Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 10/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114899 | 0.92 | P2RY6 (0.49) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL7523510 | 0.90 | P2RY6 (0.49) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL441119 | 0.89 | P2RY6 (0.42) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL2112367 | 0.87 | POLB (0.40) | P2RY6P2RY14NT5EADORA3ABL1 | |
| SCHEMBL5150767 | 0.86 | NT5E (0.49) | NT5E | |
| SCHEMBL2114858 | 0.86 | P2RY6 (0.37) | P2RY6ADORA3 | |
| SCHEMBL2114901 | 0.82 | P2RY6 (0.51) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL2113458 | 0.80 | POLB (0.38) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL2116344 | 0.80 | P2RY6 (0.43) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL332974 | 0.80 | POLB (0.49) | P2RY6P2RY14NT5EABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2021-12-28 | — | — | US | disclosed |
| CN-112955568-A | Compositions and methods for improved library enrichment | ILLUMINA公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2020-01-30 | — | — | US | disclosed |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180142239-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2018-05-24 | — | — | US | disclosed |
| US-9688982-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9200279-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200280-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-09-25 | — | — | US | disclosed |
| US-8748405-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140128324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-03-06 | — | — | US | disclosed |
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2125855-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008094254-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | P2RY6 3383/4885P2RY14 3427/4885NT5E 126/4885 |
| US-20180142239-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-20140128324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | P2RY6 2211/4885P2RY14 4332/4885NT5E 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.